Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.
Kefeli U, Benekli M, Sevinc A, Yildiz R, Kaplan MA, Ciltas A, Balakan O, Isikdogan A, Coskun U, Dane F, Harputluoglu H, Karaca H, Yazilitas D, Durnali A, Kaya AO, Demirci U, Gumus M, Buyukberber S. Kefeli U, et al. Among authors: durnali a. Oncol Lett. 2013 Aug;6(2):605-611. doi: 10.3892/ol.2013.1408. Epub 2013 Jun 17. Oncol Lett. 2013. PMID: 24137379 Free PMC article.
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.
Yildiz R, Benekli M, Ozkan M, Alkis N, Berk V, Kaplan MA, Ciltas A, Karaca H, Durnali AG, Coskun U, Dikilitas M, Sevinc A, Dane F, Yetisyigit T, Dogu GG, Buyukberber S. Yildiz R, et al. Among authors: durnali ag. J Cancer Res Clin Oncol. 2012 Nov;138(11):1845-52. doi: 10.1007/s00432-012-1264-5. Epub 2012 Jun 22. J Cancer Res Clin Oncol. 2012. PMID: 22722713
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Uncu D, Aksoy S, Çetin B, Yetişyiğit T, Özdemir N, Berk V, Dane F, Inal A, Harputluoğlu H, Budakoğlu B, Koca D, Sevinç A, Cihan S, Durnalı AG, Özkan M, Öztürk MA, Işıkdoğan A, Büyükberber S, Benekli M, Köş T, Alkış N, Karaca H, Turhal NS, Zengin N; Anatolian Society of Medical Oncology. Uncu D, et al. Among authors: durnali ag. Oncology. 2013;84(4):240-5. doi: 10.1159/000336902. Epub 2013 Feb 7. Oncology. 2013. PMID: 23392240 Clinical Trial.
Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
Inal A, Kos FT, Algin E, Yildiz R, Dikiltas M, Unek IT, Colak D, Elkiran ET, Helvaci K, Geredeli C, Dane F, Balakan O, Kaplan MA, Durnali AG, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Kucukoner M, Ozkan M, Uncu D, Benekli M, Isikdogan A. Inal A, et al. Among authors: durnali ag. Neoplasma. 2012;59(3):297-301. doi: 10.4149/neo_2012_038. Neoplasma. 2012. PMID: 22329849
Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, Dayan A, Demir L, Geredeli C, Kocer M, Arslan UY, Inal A, Unal OU, Mert AG, Bilici M, Ozkan M, Elkiran ET, Yaman S, Durnalı AG, Suner A, Alici S, Tarhan MO, Boruban C, Urakci Z, Buyukberber S. Kaplan MA, et al. Among authors: durnali ag. Oncology. 2012;83(3):141-50. doi: 10.1159/000338782. Epub 2012 Jul 18. Oncology. 2012. PMID: 22814315
Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Bozkurt O, Inanc M, Hacibekıroglu I, Esbah O, Seker M, Ulas A, Aydin K, Uysal M, Kücüköner M, Uncu D, Cıltas A, Unal OÜ, Durnali A, Demırcı U, Berk V, Tonyali O, Oksüzoglu B, Karaca H, Ozkan M. Bozkurt O, et al. Among authors: durnali a. Anticancer Res. 2014 Aug;34(8):4463-70. Anticancer Res. 2014. PMID: 25075086
Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study.
Demirci A, Alkış N, Dane F, Durnalı A, Yazıcı ÖK, Rzayev R, Kaya S, Yazılıtaş D, İnanç M, Özçelik M, Akman T, Kaplan MA, Günaydın Y, Ulaş A, Sönmez Ö, Tokluoğlu S, Gököz Doğu G, Bal Ö, Gümüş M. Demirci A, et al. Among authors: durnali a. Asia Pac J Clin Oncol. 2018 Apr;14(2):e145-e151. doi: 10.1111/ajco.12685. Epub 2017 Apr 21. Asia Pac J Clin Oncol. 2018. PMID: 28429422
Recurrence risk and prognostic parameters in stage I rectal cancers.
Cihan S, Kucukoner M, Ozdemir N, Dane F, Sendur MA, Yazilitas D, Urakci Z, Durnali A, Yuksel S, Aksoy S, Colak D, Seker MM, Taskoylu BY, Oguz A, Isikdogan A, Zengin N. Cihan S, et al. Among authors: durnali a. Asian Pac J Cancer Prev. 2014;15(13):5337-41. doi: 10.7314/apjcp.2014.15.13.5337. Asian Pac J Cancer Prev. 2014. PMID: 25040998 Free article.
Primary adult soft tissue sarcomas: analysis of 294 patients.
Alkis N, Muallaoğlu S, Koçer M, Arslan üY, Durnalı AG, Tokluoğlu S, Çelenkoğlu G, Paksoy F, Coskun U. Alkis N, et al. Med Oncol. 2011 Mar;28(1):391-6. doi: 10.1007/s12032-010-9450-2. Epub 2010 Feb 24. Med Oncol. 2011. PMID: 20180160
25 results